A citation-based method for searching scientific literature

Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
Times Cited: 201



Ele Ferrannini, Andreas Berk, Stefan Hantel, Sabine Pinnetti, Thomas Hach, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
Times Cited: 144




List of shared articles



Times cited


SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li, Fei Xie. Front Public Health 2021
0

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
62


Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci, Matteo Monami. Diabetes Obes Metab 2019
18

Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Benedetta Tomberli, Besmir Nreu, Giorgio Iacopo Baldereschi, Fabrizio Fanelli, Edoardo Mannucci, Matteo Monami. Diabetes Res Clin Pract 2019
15


Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
24

Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents.
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang, Dayong Zhang. Future Med Chem 2018
6

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Julio Rosenstock, Chantal Mathieu, Hungta Chen, Ricardo Garcia-Sanchez, Gabriela Luporini Saraiva. Arch Endocrinol Metab 2018
7

Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Vasilios Tsimihodimos, Theodosios D Filippatos, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2017
14

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
Amir Qaseem, Michael J Barry, Linda L Humphrey, Mary Ann Forciea, Nick Fitterman, Carrie Horwitch, Devan Kansagara, Robert M McLean, Timothy J Wilt. Ann Intern Med 2017
106

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court,[...]. Health Technol Assess 2017
27

Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.
F A Ribola, F B Cançado, J H M Schoueri, V F De Toni, V H R Medeiros, D Feder. Eur Rev Med Pharmacol Sci 2017
25


Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Alexander Kuhn, Jean Park, Adline Ghazi, Vanita R Aroda. Curr Cardiol Rep 2017
1

A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
A Avogaro, A Giaccari, P Fioretto, S Genovese, F Purrello, F Giorgino, S Del Prato. Expert Rev Clin Pharmacol 2017
10